Risperdal Lawsuit: En Banc Hearing Denied: Pa. Superior Court
Risperdal Lawsuit: En Banc Hearing Denied: Pa. Superior Court
Introduction
Defendants named in the Risperdal lawsuit, Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, had filed a motion early March requesting a rehearing before the entire Pennsylvania Superior Court for reconsideration of a related January 2018 ruling. On March 16, 2018, the Pennsylvania Superior Court turned down this request.
As per the January 2018 court decision, the court allowed the plaintiff involved in the lawsuit to pursue punitive damages; this decision came after a three-judge panel found that the trial court should have considered the law of plaintiffs’ home states when considering whether or not punitive damages should be allowed. Anticipating thousands of plaintiffs seeking similar awards, the defendants filed a motion to oppose the decision.
Latest News
title demo for news
Zantac Settles 4,000 Lawsuits in U.S. Courts
Sanofi has announced a settlement agreement regarding approximately 4,000 Zantac cancer lawsuits filed in state courts across the country.
…Valsartan Recall Lawsuit Set for Trial
Years after the initiation of Valsartan recalls, the U.S. District Judge overseeing lawsuits filed by individuals harmed by tainted versions of…